Drugs / QLG1091
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07487103 | May → Dec 2026 expected | type 2 diabetes mellitus | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLG1091 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07487103 ↗ |
| Route | Oral | “Oral administration once-daily.” NCT07487103 ↗ |